A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
NCT ID: NCT00269113
Last Updated: 2015-07-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
360 participants
INTERVENTIONAL
1998-09-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
NCT00472420
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
NCT01144364
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
NCT01144403
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
NCT01998893
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
rituximab [MabThera/Rituxan]
375mg/m2 iv monthly for 8 cycles
Standard chemotherapy
As prescribed
2
Standard chemotherapy
As prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rituximab [MabThera/Rituxan]
375mg/m2 iv monthly for 8 cycles
Standard chemotherapy
As prescribed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* advanced, low-grade non-Hodgkin's and mantle cell lymphoma.
Exclusion Criteria
* secondary NHL;
* participation in another clinical trial eg with cytostatic chemotherapy or cytokines;
* concomitant diseases and/or restricted organ function precluding therapy according to the study protocol.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Berlin, , Germany
Berlin, , Germany
Bochum, , Germany
Bonn, , Germany
Borna, , Germany
Chemnitz, , Germany
Cottbus, , Germany
Dresden, , Germany
Dresden, , Germany
Dülmen, , Germany
Erfurt, , Germany
Frankfurt (Oder), , Germany
Greifswald, , Germany
Güstrow, , Germany
Halle, , Germany
Halle, , Germany
Jena, , Germany
Jena, , Germany
Leipzig, , Germany
Leipzig, , Germany
Magdeburg, , Germany
Magdeburg, , Germany
Marburg, , Germany
Neubrandenburg, , Germany
Nordhausen, , Germany
Potsdam, , Germany
Riesa, , Germany
Rostock, , Germany
Rostock, , Germany
Schwerin, , Germany
Stralsund, , Germany
Trier, , Germany
Zella-Mehlis, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M39023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.